Morgan Stanley Maintains Underweight on CRISPR Therapeutics, Lowers Price Target to $42
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Terence Flynn has maintained an Underweight rating on CRISPR Therapeutics (NASDAQ:CRSP) and reduced the price target from $43 to $42.
November 13, 2023 | 2:13 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Morgan Stanley has maintained its Underweight rating on CRISPR Therapeutics and lowered the price target from $43 to $42, indicating a bearish outlook.
The reduction in price target by a major financial institution like Morgan Stanley suggests a negative outlook on the stock's value, which could lead to a decrease in investor confidence and a potential short-term decline in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100